CHRS
NASDAQCoherus Oncology Inc.
Price$1.49-0.04 (-2.93%)
01:30 PM07:45 PM
News · 26 weeks51+38%
2025-12-282026-06-21
Mix2490d
- SEC Filings9(38%)
- Insider9(38%)
- Other3(13%)
- Earnings1(4%)
- Analyst1(4%)
- Offering1(4%)
Latest news
25 items- SECCoherus Oncology Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- INSIDERDirector Satvat Ali J. was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Karachun Rita A was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Newcomer Lee Nisley was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Ryan Michael Lee was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector O'Donnell-Tormey Jill was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Wahlstrom Mats was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERDirector Newton Charles W. was granted 30,000 shares (SEC Form 4)4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Mcmichael Bryan J4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Lanfear Dennis M4 - Coherus Oncology, Inc. (0001512762) (Issuer)
- SECCoherus Oncology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form DEFA14A filed by Coherus Oncology Inc.DEFA14A - Coherus Oncology, Inc. (0001512762) (Filer)
- PRSolid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhaseMarket News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sectorNEW YORK, May 14, 2026 /CNW/ -- Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted treatments, and antibody-drug conjugates (ADCs). What's getting the industry excited is that many of these newer therapies are showi
- SECSEC Form 10-Q filed by Coherus Oncology Inc.10-Q - Coherus Oncology, Inc. (0001512762) (Filer)
- SECCoherus Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Coherus Oncology, Inc. (0001512762) (Filer)
- PRCoherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the first quarter
- ANALYSTGuggenheim initiated coverage on Coherus BioSciences with a new price targetGuggenheim initiated coverage of Coherus BioSciences with a rating of Buy and set a new price target of $12.00
- SECSEC Form DEFA14A filed by Coherus Oncology Inc.DEFA14A - Coherus Oncology, Inc. (0001512762) (Filer)
- PRCoherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 11, 2026, starting at 5:00 p.m. Eastern Standard Time To access the conference call, please pre-register through the followin
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Coherus Oncology Inc.SCHEDULE 13G/A - Coherus Oncology, Inc. (0001512762) (Subject)
- SECSEC Form DEF 14A filed by Coherus Oncology Inc.DEF 14A - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form DEFA14A filed by Coherus Oncology Inc.DEFA14A - Coherus Oncology, Inc. (0001512762) (Filer)
- SECSEC Form PRE 14A filed by Coherus Oncology Inc.PRE 14A - Coherus Oncology, Inc. (0001512762) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Coherus Oncology Inc.SCHEDULE 13G/A - Coherus Oncology, Inc. (0001512762) (Subject)
- SECSEC Form 10-K filed by Coherus Oncology Inc.10-K - Coherus Oncology, Inc. (0001512762) (Filer)
CHRS FAQ
7 questionsWhat does Coherus Oncology Inc. do?
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and...Where does CHRS stock trade?
Coherus Oncology Inc. (CHRS) is listed on NASDAQ.What sector and industry is CHRS in?
Coherus Oncology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Coherus Oncology Inc. go public?
Coherus Oncology Inc. (CHRS) completed its IPO in 2014.What are analysts saying about CHRS?
Coherus Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $1200.00 price target on 2026-05-11.What companies are similar to CHRS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CHRS side-by-side with any of them on Quantisnow.How can I track CHRS on Quantisnow?
Quantisnow aggregates Coherus Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CHRS to receive live email and push alerts on every new disclosure.